---
title: "VeraDermics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295535716.md"
datetime: "2026-08-11T12:18:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295535716.md)
  - [en](https://longbridge.com/en/news/295535716.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295535716.md)
generator: "portal-rs"
---

# VeraDermics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -28.34 M.

The provided Form 8-K filing by Veradermics, Incorporated, dated August 11, 2026, announces the issuance of a press release regarding the company’s financial results for the quarter ended June 30, 2026. However, the filing explicitly states that the actual financial and operational metrics, including segment revenue, net income, gross margin, operating profit, cash flow, or any forward-looking outlook or guidance, are not contained within this document. The press release containing these results is furnished as Exhibit 99.1, which was not included in the provided text.

### Related Stocks

- [MANE.US](https://longbridge.com/en/quote/MANE.US.md)

## Related News & Research

- [Bamco Inc. NY Purchases 169,913 Shares of Veradermics, Incorporated $MANE](https://longbridge.com/en/news/297140282.md)
- [JOYY beats top-line and bottom-line estimates; gives FY 2026 outlook](https://longbridge.com/en/news/296985959.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [Paratus Energy announces Q2 2026 cash dividend of USD 0.22 per share](https://longbridge.com/en/news/297268195.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**